Advertisement

Emergent Reversal of Antithrombotics and Treatment of Life-Threatening Bleeding from Coagulopathies: A Clinical Review

      Highlights

      • Bleeding caused by anticoagulants or coagulopathies is a challenging scenario
      • Timely selection of treatment strategies is highly important
      • Five tables provide guidance when treating emergent bleeding

      Abstract

      Background

      Reversal of antithrombotic agents and treatment of life-threatening bleeding episodes from coagulopathies can be a stressful scenario for clinicians, especially when the selection of treatment options should occur quickly. Understanding the options available for these agents requires emergency physicians to be familiar with the current data surrounding new therapies and dosing strategies for the treatment of bleeding from reversible and nonreversible antithrombotics and coagulopathic conditions.

      Objective

      To provide quick resource guides for the reversal of major or life-threatening bleeding caused by antithrombotic agents or in the setting of coagulopathies.

      Methods

      A literature search for articles published through September 2021 related to antithrombotic reversal and treatment of acute bleeding from coagulopathies was conducted using the PubMed clinical database. Selected articles were used to generate 5 guidance tables in this clinical review.

      Discussion

      Four guidance tables for how to treat major or life-threatening bleeding from antithrombotic agents and 1 table for how to manage life-threatening bleeding for coagulopathies are presented as a quick reference tool for the emergency physician. Additional information on upcoming reversal agents and possible treatment options are provided herein.

      Conclusions

      In this clinical review, a series of 5 tables were created to provide quick and comprehensive guidance for the emergency physician when treating major or life-threatening bleeding caused by antithrombotic agents or coagulopathies. © 2022 Elsevier Inc.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ageno W
        • Gallus AS
        • Wittkowsky A
        • et al.
        Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e44S-e88S
        • Schulman S
        • Beyth RJ
        • Kearon C
        • et al.
        Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition).
        Chest. 2008; 133 (257S–98S)
        • Frontera JA
        • Lewin JJ
        • Rabinstein AA
        • et al.
        Guideline for reversal of antithrombotics in intracranial hemorrhage.
        Neurocrit Care. 2016; 24: 6-46
        • Vane JR
        • Botting RM.
        Mechanism of action of nonsteroidal anti-inflammatory drugs.
        Am J Med. 1998; 104: 2S-8S
        • Ageno W
        • Garcia D
        • Aguilar MI
        • et al.
        Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: treatment.
        Am J Hematol. 2009; 84: 584-588
        • Garcia D
        • Ageno W
        • Bussey H
        • et al.
        Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 1: trevention.
        Am J Hematol. 2009; 84: 579-583
        • Garcia DA
        • Baglin TP
        • Weitz JI
        • et al.
        Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e24S-e43S
        • Crowther MA
        • Warkentin TE.
        Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents.
        J Thromb Haemost. 2009; 7: 107-110
        • Berntorp E
        • Astermark J
        • Baghaei F
        • et al.
        Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment.
        Haemophilia. 2012; 18: 158-165
        • Nichols WL
        • Hultin MB
        • James AH
        • et al.
        von Willebrand disease (VWD): Evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) expert panel report.
        Haemophilia. 2008; 14: 171-232
        • Kruse-Jarres R
        • Kempton CL
        • Baudo F
        • et al.
        Acquired hemophilia A: updated review of evidence and treatment guidance.
        Am J Hematol. 2017; 92: 695-705
        • Tiede A
        • Worster A.
        Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia.
        Ann Hematol. 2018; 97: 1889-1901
        • Markis M.
        Systematic review of the management of patients with haemophilia A and inhibitors.
        Blood Coagul Fibrinolysis. 2004; 15: S25-S27
        • Neunert C
        • Lim W
        • Crowther M
        • et al.
        The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.
        Blood. 2011; 117: 4190-4207
        • Medow JE
        • Dierks MR
        • Williams E
        • et al.
        The emergent reversal of coagulopathies encountered in neurosurgery and neurology: a technical note.
        Clin Med Res. 2015; 13: 20-31
        • Schulman S
        • Kearon C.
        Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.
        J Thromb Haemost. 2005; 3: 692-694
        • Schulman S
        • Angeras U
        • Bergqvist D
        • et al.
        Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients.
        J Thromb Haemost. 2010; 8: 202-204
        • Tomaselli GF
        • Mahaffey KW
        • Cuker A
        • et al.
        2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants.
        J Am Coll Cardiol. 2020; 76: 594-622
        • Witt DM
        • Nieuwlaat R
        • Clark NP
        • et al.
        American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.
        Blood Adv. 2018; 2: 3257-3291
        • Holbrook A
        • Schulman S
        • Witt DM
        • et al.
        Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141 (e152S–84S)
        • Goldstein JN
        • Refaai MA
        • Milling TJ
        • et al.
        Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.
        Lancet. 2015; 385: 2077-2087
        • Frontera JA
        • Gordon E
        • Zach V
        • et al.
        Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage.
        Neurocrit Care. 2014; 21: 397-406
        • Hickey M
        • Gatien M
        • Taljaard M
        • et al.
        Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department.
        Circulation. 2013; 128: 360-364
        • Chai-Adisaksopha C
        • Hillis C
        • Siegal DM
        • et al.
        Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal: a systematic review and meta-analysis.
        Thromb Haemost. 2016; 116: 879-890
        • Popovsky MA.
        Transfusion-related acute lung injury: incidence, pathogenesis and the role of multicomponent apheresis in its prevention.
        Transfus Med Hemotherap. 2008; 35: 76-79
        • Tsu L V
        • Dienes JE
        • Dager WE.
        Vitamin K dosing to reverse warfarin based on INR, route of administration and home warfarin dose in the acute/critical care setting.
        Ann Pharmacother. 2012; 46: 1617-1626
        • Abdoellakhan RA
        • Miah IP
        • Khorsand N
        • et al.
        Fixed versus variable dosing of prothrombin complex concentrate in vitamin K antagonist-related intracranial hemorrhage: a retrospective analysis.
        Neurocrit Care. 2017; 26: 64-69
        • Kantorovich A
        • Fink JM
        • Militello MA
        • et al.
        Low-dose 3-factor prothrombin complex concentrate for warfarin reversal prior to heart transplant.
        Ann Pharmacother. 2015; 49: 876-882
        • Klein L
        • Peters J
        • Miner J
        • et al.
        Evaluation of fixed dose 4-factor prothrombin complex concentrate for emergent warfarin reversal.
        Am J Emerg Med. 2015; 33: 1213-1218
        • Quick JA
        • Meyer JM
        • Coughenour JP
        • et al.
        Less is more: low-dose prothrombin complex concentrate effective in acute care surgery patients.
        Am Surg. 2015; 81: 646-650
        • Varga C
        • Al-Touri S
        • Papadoukakis S
        • et al.
        The effectiveness and safety of fixed low-dose prothrombin complex concentrates in patients requiring urgent reversal of warfarin.
        Transfusion. 2013; 53: 1451-1458
        • Khorsand N
        • Veeger NJ
        • van Hest RM
        • et al.
        An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies.
        Haematologica. 2012; 97: 1501-1506
        • Bizzell AC
        • Mousavi MK
        • Yin E.
        Fixed- versus variable-dose prothrombin complex concentrate protocol for vitamin K antagonist reversal.
        Int J Hematol. 2021; 114: 334-341
        • Dietrich SK
        • Mixon M
        • Holowatyj M
        • et al.
        Multi-centered evaluation of a novel fixed-dose four-factor prothrombin complex concentrate protocol for warfarin reversal.
        Am J Emerg Med. 2020; 38: 2096-2100
        • McMahon C
        • Halfpap J
        • Zhao Q
        • et al.
        Evaluation of a fixed-dose regimen of 4-factor prothrombin complex concentrate for warfarin reversal.
        Ann Pharmacother. 2021; 55: 1230-1235
        • Majeed A
        • Ågren A
        • Holmström M
        • et al.
        Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.
        Blood. 2017; 130: 1706-1712
        • Schulman S
        • Gross PL
        • Ritchie B
        • et al.
        Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study.
        Thromb Haemost. 2018; 118: 842-851
        • Cuker A
        • Burnett A
        • Triller D
        • et al.
        Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum.
        Am J Hematol. 2019; 94: 697-709
        • Kim C
        • Cottingham L
        • Eberwein K
        • et al.
        Comparison of hemostatic outcomes in patients receiving fixed-dose vs. weight-based 4-factor prothrombin complex concentrate.
        J Emerg Med. 2020; 59: 25-32
        • Berger K
        • Santibañez M
        • Lin L
        • et al.
        A low-dose 4F-PCC protocol for DOAC-associated intracranial hemorrhage.
        J Intensive Care Med. 2020; 35: 1203-1208
        • Allison TA
        • Lin PJ
        • Gass JA
        • et al.
        Evaluation of the use of low-dose 4-factor prothrombin complex concentrate in the reversal of direct oral anticoagulants in bleeding patients.
        J Intensive Care Med. 2020; 35: 903-908
        • Hormese M
        • Littler A
        • Doane B
        • et al.
        Comparison of high- and low-dose 4-factor prothrombin complex concentrate for the emergent reversal of oral factor Xa inhibitors.
        J Thromb Thrombolysis. 2021; 52: 828-835
        • Castillo R
        • Chan A
        • Atallah S
        • et al.
        Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
        J Thromb Thrombolysis. 2021; 51: 151-158
        • Milioglou I
        • Farmakis I
        • Neudeker M
        • et al.
        Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis.
        J Thromb Thrombolysis. 2021; 52: 1137-1150
        • Wilsey HA
        • Bailey AM
        • Schadler A
        • et al.
        Comparison of low- versus high-dose four-factor prothrombin complex concentrate (4F-PCC) for factor Xa inhibitor–associated bleeding: a retrospective study.
        J Intensive Care Med. 2021; 36: 597-603
        • Highsmith EA
        • Morton C
        • Varnado S
        • et al.
        Outcomes associated with 4-factor prothrombin complex concentrate administration to reverse oral factor Xa inhibitors in bleeding patients.
        J Clin Pharmacol. 2021; 61: 598-605
        • Pollack CV
        • Reilly PA
        • Eikelboom J
        • et al.
        Idarucizumab for dabigatran reversal.
        N Engl J Med. 2015; 373: 511-520
        • Gómez-Outes A
        • Alcubilla P
        • Calvo-Rojas G
        • et al.
        Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants.
        J Am Coll Cardiol. 2021; 77: 2987-3001
        • Luo C
        • Chen F
        • Chen YH
        • et al.
        Prothrombin complex concentrates and andexanet for management of direct factor Xa inhibitor related bleeding: a meta-analysis.
        Eur Rev Med Pharmacol Sci. 2021; 25: 2637-2653
        • Nederpelt CJ
        • Naar L
        • Krijnen P
        • et al.
        Andexanet alfa or prothrombin complex concentrate for factor Xa inhibitor reversal in acute major bleeding: a systematic review and meta-analysis.
        Crit Care Med. 2021; 49: E1025-E1036
        • Connolly SJ
        • Crowther M
        • Eikelboom JW
        • et al.
        Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors.
        N Engl J Med. 2019; 380: 1326-1335
        • Ansell JE
        • Bakhru SH
        • Laulicht BE
        • et al.
        Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban.
        Thromb Haemost. 2017; 117: 238-245
        • Ansell J
        • Bakhru S
        • Laulicht BE
        • et al.
        Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects.
        Eur Heart J. 2021; 00: 1-8
        • Bordes J
        • Asencio Y
        • Kenane N
        • et al.
        Recombinant activated factor VII for acute subdural haematoma in an elderly patient taking fondaparinux.
        Br J Anaesth. 2008; 101: 575-576
        • Firozvi K
        • Deveras RAE
        • Kessler CM.
        Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate.
        Am J Hematol. 2006; 81: 582-589
        • Sweidan AJ
        • Singh NK
        • Conovaloff JL
        • et al.
        Coagulopathy reversal in intracerebral haemorrhage.
        Stroke Vasc Neurol. 2020; 5: 29-33
        • Gratz I
        • Koehler J
        • Olsen D
        • et al.
        The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations.
        J Thorac Cardiovasc Surg. 1992; 104: 1417-1422
        • Flordal PA
        • Sahlin S.
        Use of desmopressin to prevent bleeding complications in patients treated with aspirin.
        Br J Surg. 1993; 80: 723-724
        • Naidech AM
        • Liebling SM
        • Rosenberg NF
        • et al.
        Early platelet transfusion improves platelet activity and may improve outcomes after intracerebral hemorrhage.
        Neurocrit Care. 2012; 16: 82-87
        • Ranucci M
        • Nano G
        • Pazzaglia A
        • et al.
        Platelet mapping and desmopressin reversal of platelet inhibition during emergency carotid endarterectomy.
        J Cardiothorac Vasc Anesth. 2007; 21: 851-854
        • Leithauser B
        • Zielske D
        • Seyfert U
        • et al.
        Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel.
        Clin Hemorheol Microcirc. 2008; 39: 293-302
        • Teng R
        • Mitchell PD
        • Butler K.
        The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor.
        J Clin Pharm Ther. 2014; 39: 186-191
        • Baharoglu MI
        • Cordonnier C
        • Salman RAS
        • et al.
        Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial.
        Lancet. 2016; 387: 2605-2613
        • Washington CW
        • Schuerer DJE
        • Grubb RL.
        Platelet transfusion: an unnecessary risk for mild traumatic brain injury patients on antiplatelet therapy.
        J Trauma. 2011; 71: 358-363
        • Ducruet AF
        • Hickman ZL
        • Zacharia BE
        • et al.
        Impact of platelet transfusion on hematoma expansion in patients receiving antiplatelet agents before intracerebral hemorrhage.
        Neurol Res. 2010; 32: 706-710
        • Brogi E
        • Corbella D
        • Coccolini F
        • et al.
        The role of platelet transfusions after intracranial hemorrhage in patients on antiplatelet agents: a systematic review and meta-analysis.
        World Neurosurg. 2020; 141: 455-466
        • Post R
        • Tjerkstra MA
        • Middeldorp S
        • et al.
        Platelet transfusion in patients with aneurysmal subarachnoid hemorrhage is associated with poor clinical outcome.
        Sci Rep. 2020; 10: 1-7
        • Bhatt DL
        • Pollack C V
        • Weitz JI
        • et al.
        Antibody-based ticagrelor reversal agent in healthy volunteers.
        N Engl J Med. 2019; 380: 1825-1833
        • Grainger JD
        • Thachil J
        • Will AM.
        How we treat the platelet glycoprotein defects; Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults.
        Br J Haematol. 2018; 182: 621-632
        • Triulzi DJ
        • Blumberg N.
        Variability in response to cryoprecipitate treatment for hemostatic defects in uremia.
        Yale J Biol Med. 1990; 63: 1-7
        • Hedges SJ
        • Dehoney SB
        • Hooper JS
        • et al.
        Evidence-based treatment recommendations for uremic bleeding.
        Nat Clin Pract Nephrol. 2007; 3: 138-153
        • Janson PA
        • Jubelirer SJ
        • Weinstein MJ
        • et al.
        Treatment of the bleeding tendency in uremia with cryoprecipitate.
        N Engl J Med. 2009; 303: 1318-1322
        • Livio M
        • Mannucci PM
        • Viganò G
        • et al.
        Conjugated estrogens for the management of bleeding associated with renal failure.
        N Engl J Med. 2009; 315: 731-735
        • Mannucci PM
        • Remuzzi G
        • Pusineri F
        • et al.
        Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia.
        N Engl J Med. 2010; 308: 8-12
        • Knoebl P
        • Thaler J
        • Jilma P
        • et al.
        Emicizumab for the treatment of acquired hemophilia A.
        Blood. 2021; 137: 410-419
        • Möhnle P
        • Pekrul I
        • Spannagl M
        • et al.
        Emicizumab in the treatment of acquired haemophilia: a case report.
        Transfus Med Hemotherapy. 2019; 46: 123
        • Tran T
        • Arnall J
        • Moore DC
        • et al.
        Vonicog alfa for the management of von Willebrand disease: a comprehensive review and single-center experience.
        J Thromb Thrombolysis. 2020; 49: 431-440
        • Othman M
        • Gresele P.
        Guidance on the diagnosis and management of platelet-type von Willebrand disease: a communication from the Platelet Physiology Subcommittee of the ISTH.
        J Thromb Haemost. 2020; 18: 1855-1858
        • Tebo C
        • Gibson C
        • Mazer-Amirshahi M.
        Hemophilia and von Willebrand disease: a review of emergency department management.
        J Emerg Med. 2020; 58: 756-766
        • Dolan G
        • Benson G
        • Duffy A
        • et al.
        Haemophilia B: where are we now and what does the future hold?.
        Blood Rev. 2018; 32: 52-60
        • Kempton CL
        • Meeks SL.
        Toward optimal therapy for inhibitors in hemophilia.
        Blood. 2014; 124: 3365-3372
        • Squizzato A
        • Hunt BJ
        • Kinasewitz GT
        • et al.
        Supportive management strategies for disseminated intravascular coagulation: an international consensus.
        Thromb Haemost. 2016; 115: 896-904
        • Mohan G
        • Malayala SV
        • Mehta P
        • et al.
        A comprehensive review of congenital platelet disorders, thrombocytopenias and thrombocytopathies.
        Cureus. 2020; 12: 1-8
        • Nurden AT
        • Freson K
        • Seligsohn U.
        Inherited platelet disorders.
        Haemophilia. 2012; 18: 154-160
        • Allison MG
        • Shanholtz CB
        • Sachdeva A.
        Hematological issues in liver disease.
        Crit Care Clin. 2016; 32: 385-396
        • Scully M
        • Hunt BJ
        • Benjamin S
        • et al.
        Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.
        Br J Haematol. 2012; 158: 323-335
        • Montrief T
        • Koyfman A
        • Long B.
        Acute liver failure: a review for emergency physicians.
        Am J Emerg Med. 2019; 37: 329-337
        • Stotts MJ
        • Davis JPE
        • Shah NL.
        Coagulation testing and management in liver disease patients.
        Curr Opin Gastroenterol. 2020; 36: 169-176
        • Cooper N
        • Ghanima W.
        Immune thrombocytopenia.
        N Engl J Med. 2019; 381: 945-955
        • Mithoowani S
        • Cervi A
        • Shah N
        • et al.
        Management of major bleeds in patients with immune thrombocytopenia.
        J Thromb Haemost. 2020; 18: 1783-1790
        • Bolton-Maggs PHB
        • Chalmers EA
        • Collins PW
        • et al.
        A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO.
        Br J Haematol. 2006; 135: 603-633
        • Almomani MH
        • Mangla A.
        Bernard Soulier syndrome.
        StatPearls Publishing, Treasure Island, FL2021
        • Northup PG
        • Garcia-Pagan JC
        • Garcia-Tsao G
        • et al.
        Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases.
        Hepatology. 2021; 73: 366-413
        • Simonetto DA
        • Singal AK
        • Garcia-Tsao G
        • et al.
        ACG clinical guideline: disorders of the hepatic and mesenteric circulation.
        Am J Gastroenterol. 2020; 115: 18-40
        • Adelborg K
        • Larsen JB
        • Hvas AM.
        Disseminated intravascular coagulation: epidemiology, biomarkers, and management.
        Br J Haematol. 2021; 192: 803-818
        • Khan AI
        • Anwer F.
        Platelet Transfusion.
        StatPearls Publishing, Treasure Island, FL2021
        • Smythe MA
        • Priziola J
        • Dobesh PP
        • et al.
        Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism.
        J Thromb Thrombolysis. 2016; 41: 165-186
        • Holstein K
        • Liu X
        • Smith A
        • et al.
        Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study.
        Blood. 2020; 136: 279-287
        • Tiede A
        • Collins P
        • Knoebl P
        • et al.
        International recommendations on the diagnosis and treatment of acquired hemophilia A.
        Haematologica. 2020; 105: 1791-1801
        • Bornikova L
        • Peyvandi F
        • Allen G
        • et al.
        Fibrinogen replacement therapy for congenital fibrinogen deficiency.
        J Thromb Haemost. 2011; 9: 1687-1704
        • Odame JE
        • Chan AK
        • Wu JK
        • et al.
        Factor XIII deficiency management: a review of the literature.
        Blood Coagul Fibrinolysis. 2014; 25: 199-205
        • Pelcovits A
        • Schiffman F
        • Niroula R.
        Factor XIII deficiency: a review of clinical presentation and management.
        Hematol Oncol Clin North Am. 2021; 35: 1171-1180